Related Experiment Video

Updated: May 9, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Advances from clinical trials in juvenile idiopathic arthritis

Daniel J Lovell1, Nicola Ruperto, Edward H Giannini

  • 1Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA. daniel.lovell@cchmc.org

Nature Reviews. Rheumatology
|July 11, 2013
PubMed

Insights

Advances in biologic treatments have transformed juvenile idiopathic arthritis (JIA) care. This progress is built upon decades of dedicated pediatric rheumatology research, clinical trials, and regulatory support for pediatric studies.

Area of Science:

  • Pediatric Rheumatology
  • Clinical Trial Methodology
  • Biologic Therapies

Background:

  • Juvenile idiopathic arthritis (JIA) treatments have significantly advanced over the last 15 years.
  • The development of biologic treatments has been a major driver of these improvements.
  • Early recognition of the need for pediatric clinical trials by rheumatologists laid the groundwork for current progress.

Approach:

  • International pediatric rheumatology networks have been established and refined for conducting clinical trials.
  • Development of validated outcomes and methodologies has been crucial for trial success.
  • Regulatory frameworks, including FDA and EMA legislation, mandate pediatric studies before drug licensing for children.

Key Points:

  • The evolution of pediatric rheumatology networks has enabled robust clinical trial execution.
  • Validated outcome measures and standardized methodologies are essential for reliable JIA research.
  • Legislative support from agencies like the FDA and EMA is critical for advancing pediatric drug development.

Conclusions:

  • Current research focuses on disease-specific registries, personalized medicine, and standardized treatment protocols for JIA.
  • Continued collaboration and methodological refinement are key to further enhancing JIA treatment options.
  • The historical commitment to pediatric clinical trials has paved the way for modern therapeutic advancements in JIA.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...